Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (TTRX)
Company Research
Source: Business Wire
Phase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026Secured up to $25 Million in Growth Capital from Avenue Capital GroupStrengthened Leadership Team via Appointments of Dr. Robert Redfield and Martin Dewhurst LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results for the year ended December 31, 2025, and provided corporate updates.“Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “Our Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis remains on track for topline results in mid-2026, positioning us to advance a potential first-line therapy in atopic dermatitis. Securing up to $25 millio
Show less
Read more
Impact Snapshot
Event Time:
TTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TTRX alerts
High impacting Turn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TTRX
News
- Turn Therapeutics Secures $25M Financing for Dermatology Trials [Los Angeles Times (CA)]Los Angeles Times
- Turn Therapeutics (TTRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $8.00 price target on the stock.MarketBeat
- Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital GroupBusiness Wire
- Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory AffairsBusiness Wire
- Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]Yahoo! Finance
TTRX
Sec Filings
- 4/6/26 - Form SCHEDULE
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- TTRX's page on the SEC website